Last updated: February 13, 2026
Dacomitinib (brand name: Vizura) is an orally administered, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Approved by the FDA in 2018 for treatment of first-line non-small cell lung carcinoma (NSCLC) with EGFR exon 19 or 21 mutations, its market prospects are shaped by competitive, patent, regulatory, and clinical factors.
Market Overview
Competitive Landscape
Dacomitinib faces competition primarily from osimertinib (Tagrisso), which has broader approval and a stronger position based on clinical outcomes. Osimertinib's approval in 2018 for first-line NSCLC and its superior efficacy metrics diminish dacomitinib's market share.
- Key competitors:
- Osimertinib (AstraZeneca)
- Erlotinib (Tarceva)
- Gefitinib (Iressa)
Market Size
The global NSCLC therapeutics market was valued at approximately USD 8.2 billion in 2020 and is expected to grow at a CAGR of 8.3%, reaching USD 15 billion by 2027[1]. Dacomitinib's target segment is a subset within this market, primarily within first-line EGFR-mutant NSCLC.
- Prevalence of EGFR mutations: 10-15% in Western populations, up to 40% in Asian populations.
- Market penetration: Limited, due to competition and clinical positioning.
Regulatory and Patent Landscape
Dacomitinib's patent protection was initially secured through baseline patents expiring around 2025-2027 in the U.S. and Europe, with extensions possibly pending. Post-patent expiration, generic versions could enter the market, significantly reducing revenue.
- Regulatory approvals: FDA (2018), EMA (2019)
- Indication expansion efforts: Clinical trials for other EGFR-driven cancers ongoing but limited success.
Clinical Efficacy and Adoption Dynamics
Key clinical trials indicate dacomitinib's efficacy is comparable to osimertinib but with higher toxicity, impacting its adoption rate.
- ARCHER 1050 trial results:
- Median progression-free survival (PFS): 14.7 months vs 9.2 months for gefitinib.
- Overall survival (OS): 27.5 months vs. 24.3 months.
- Higher adverse events: rash, diarrhea, dry skin.
Drug adoption is constrained by safety profile, leading oncologists to prefer osimertinib, which has a more favorable side-effect profile.
Sales and Revenue Trends
Global sales for dacomitinib have been modest to date.
| Year |
Estimated Sales (USD millions) |
Market Share in EGFR Inhibitors |
| 2018 |
15 |
2% |
| 2019 |
20 |
2.5% |
| 2020 |
25 |
3% |
| 2021 |
30 |
3.5% |
The growth rate remains capped by limited clinical differentiation and competition from more tolerated agents. Future sales may accelerate if new indications gain regulatory approval or if combination therapies improve efficacy.
Growth Drivers and Challenges
Growth Drivers
- Expansion into second-line and other NSCLC patient subsets.
- Clinical trials exploring combinations with immunotherapies.
- Potential indication expansion into other EGFR-driven cancers.
Challenges
- Competition from osimertinib and other EGFR inhibitors.
- Toxicity profile limiting widespread use.
- Patent expiration risks around 2025-2027.
- Limited marketing reach as a second-line agent in regions where osimertinib is dominant.
Financial Outlook
Projected revenues hinge on several factors:
- Market penetration: Minimal currently but may scale with new approvals.
- Patent lifecycle: Limited upside beyond 2027 without approval for additional indications.
- Pricing dynamics: Standard EGFR inhibitor pricing (~USD 10,000–USD 15,000 per year in the U.S.).
Assuming modest market share increases and stable pricing, revenue forecasts remain conservative:
| Year |
Revenue Estimate (USD millions) |
Growth Rate |
| 2022 |
35 |
16.7% |
| 2023 |
45 |
28.6% |
| 2024 |
55 |
22.2% |
| 2025 |
60 |
9.1% |
Post-patent expiry, revenue decline is expected unless brand extensions or indications are approved.
Key Takeaways
- Dacomitinib is a late entrant with limited market penetration compared to established competitors, primarily osimertinib.
- Its clinical efficacy is comparable but toxicity limits uptake.
- Revenue growth remains limited, with a peak around 2025, before patent expiration risks materialize.
- Future market expansion relies on additional indications, improved formulations, or combination therapies.
- The patent horizon and competitive landscape heavily influence financial projections.
FAQs
1. What are the primary factors limiting dacomitinib's market share?
Clinical toxicity, competition from osimertinib, and limited indication expansion restrict market share.
2. When is patent expiration expected, and how will it affect revenues?
Patents are expected to expire between 2025 and 2027, leading to generic entry and a sharp revenue decline.
3. Can dacomitinib be used in other cancers?
Research is ongoing, but current approvals are limited to EGFR-mutant NSCLC; expansion prospects are uncertain.
4. How does dacomitinib compare to osimertinib clinically?
Dacomitinib has similar efficacy but higher toxicity, making it less favored in clinical practice.
5. What are the growth prospects beyond 2025?
Growth assumes successful indication expansion, combination therapies, or market niche positioning; otherwise, revenue decline is expected.
References
- Grand View Research. "NSCLC Therapeutics Market Size & Trends," 2021.
- U.S. FDA. "Dacomitinib Approval Announcement," 2018.
- ClinicalTrials.gov. "Dacomitinib Trials," 2022.
- IQVIA. "Pharmaceutical Market Data," 2021.
